CTLA4 Promoter -318C/T — The Upstream Regulator
CTLA-4 (Cytotoxic T-Lymphocyte Associated Protein 4) is one of the immune system's most
critical brakes. While much attention has focused on functional coding variants in CTLA4,
the promoter also harbours a polymorphism that influences how much CTLA-4 is made in the
first place. rs5742909, the -318C/T variant, sits 318 base pairs upstream of the
CTLA4 transcription start site | Upstream variants in this position regulate transcription
factor access and gene activation thresholds
and modulates gene expression by altering promoter activity. The T allele is associated
with higher CTLA-4 mRNA and cell-surface protein, potentially strengthening the immune
checkpoint — and paradoxically this makes carriers more responsive to abatacept, a drug
that mimics CTLA-4 function.
The Mechanism
The -318 position lies within a core promoter region that binds transcription factors
controlling CTLA4 activation in T cells. Luciferase reporter assays have shown that the
T allele produces significantly higher promoter activity | Relative luciferase units:
8.13 ± 0.46 for T allele vs 6.87 ± 0.49 for C allele.
More recent analysis identified LEF1 and TCF7 as transcription factors that bind
differentially at this position | Electrophoretic mobility shift assays show increased
band intensity for the T allele, indicating stronger transcription factor binding, with the T allele enhancing
TCF7-mediated transcriptional activation in Jurkat T cells.
In cellular expression studies, individuals carrying the T allele at -318 combined with
the AA genotype at the exon 1 Thr17Ala position (rs231775) | The two variants can act
synergistically — the promoter variant controls transcription while the coding variant
affects protein trafficking showed significantly
higher CTLA-4 cell-surface expression after cellular stimulation and elevated CTLA-4 mRNA
in non-stimulated cells. This suggests the -318T allele primarily upregulates basal
transcription, while stimulation-induced expression is jointly regulated by both the
promoter and coding regions.
The net functional result: T allele carriers have a modestly more active CTLA-4 checkpoint
at baseline. Whether this constitutes protection from autoimmune disease or a subtle shift
in immune tone depends strongly on the disease context and interacting genetic background.
The Evidence
Autoimmune disease associations — mixed picture:
The -318C/T variant has been intensively studied across autoimmune conditions, and the
overall conclusion is one of inconsistency across populations and diseases.
For Graves' disease and Hashimoto's thyroiditis, a meta-analysis of 29 independent studies
including 3,614 cases and 8,839 controls | Shi et al. 2018, published in Thyroid Research found no statistically significant association
between the -318C/T polymorphism and Hashimoto's risk in any of the tested genetic models
(allelic, codominant, dominant, or recessive). A large case-control study in Han Chinese
| 289 adult Graves' disease, 265 pediatric Graves', 229 pediatric Hashimoto's, 1,058 controls similarly found no association for -318C/T, while
the +49A/G (rs231775) and CT60 (rs3087243) variants in the same gene showed significant risk.
For rheumatoid arthritis, a meta-analysis of 10 studies including 2,477 patients and 2,941
controls | Comprehensive pooled analysis across Caucasian, Asian, and Latin American populations pooled results across multiple genetic models and
found no significant association between rs5742909 and RA susceptibility in any ethnicity.
The T allele OR for allelic comparison was 1.21 (95% CI 0.93–1.57, P=0.15), which did not
reach significance. The -318 promoter variant is not the primary CTLA4 determinant of most
autoimmune disease risk.
Abatacept pharmacogenomics — the strongest actionable signal:
The most clinically relevant finding for rs5742909 comes from a retrospective cohort study
of 109 RA patients | Kowalska-Kępczyńska et al. 2020, MDPI Journal of Personalized Medicine treated with abatacept (a CTLA-4-Ig fusion
protein used in biologic RA therapy). Patients carrying at least one copy of the T allele
showed substantially better treatment outcomes: EULAR response at 12 months was associated
with the T allele at OR = 5.88 (95% CI: 1.48–23.29), and achievement of low disease activity
showed OR = 4.75. The same study identified rs231775 G allele as an independent predictor
in the same dataset, suggesting the two CTLA4 variants may additively inform treatment
selection. Remission rates were further improved in patients who initiated abatacept earlier
and had fewer prior biologic failures.
This pharmacogenomic signal is biologically plausible: abatacept works by mimicking CTLA-4
and blocking CD28 co-stimulation of T cells. Patients whose T cells already express more
CTLA-4 (T allele carriers) may have a disease phenotype particularly driven by co-stimulation
pathways that abatacept targets, making the drug especially effective for them.
Practical Implications
For most people, the -318C/T variant is a background autoimmune susceptibility modifier
rather than a primary disease determinant. The strongest single-SNP CTLA4 signals for
autoimmune diseases — Graves', Hashimoto's, SLE, T1D — come from rs231775 (Thr17Ala)
and rs3087243 (CT60), not from this promoter variant. The -318C/T result should be
interpreted alongside those variants.
The clearest clinical application is in rheumatoid arthritis patients considering abatacept.
If you carry the T allele, the available evidence — though from a single retrospective study —
suggests meaningfully better odds of achieving EULAR response or low disease activity on
abatacept. This is worth raising with a rheumatologist when discussing biologic treatment
options, as CTLA4 genotyping is not yet routine practice but may inform treatment sequencing.
Interactions
rs5742909 is in partial linkage disequilibrium with rs231775 (Thr17Ala) and rs3087243
(CT60). The interaction between the -318T allele and rs231775 AA genotype is particularly
notable: combined carriers show enhanced CTLA-4 expression above either variant alone |
Studies of cell-surface CTLA-4 density show synergistic effects when both protective
alleles are co-inherited. This means that
interpreting rs5742909 in isolation is less informative than examining the full CTLA4
haplotype.
The CTLA4 locus also interacts epistatically with PTPN22 rs2476601, another T cell
regulatory variant. In conditions like SLE and T1D, the combined CTLA4 + PTPN22 genotype
profile confers a substantially different risk landscape than either gene alone.
For abatacept response in RA, co-carriage of the rs5742909 T allele and rs231775 G allele
may be additive — the same study that identified rs5742909 as a predictor also found
independent contributions from rs231775, consistent with these variants acting through
partially complementary mechanisms (transcription vs. protein trafficking).
All Genotypes
Standard CTLA4 promoter activity with typical immune checkpoint expression
You have two copies of the C allele at the CTLA4 -318 promoter position. This is the most common genotype globally — approximately 87% of people carry this configuration. Your CTLA-4 baseline promoter activity falls within the typical range, and this variant alone does not significantly alter your risk for most autoimmune diseases studied. Autoimmune risk in your case is better assessed through rs231775 (Thr17Ala) and rs3087243 (CT60), the primary CTLA4 susceptibility variants.
One copy of the promoter T allele associated with higher CTLA-4 expression and better abatacept response
You carry one copy of the T allele at the CTLA4 -318 promoter position. About 13% of people globally carry one copy of the T allele. This variant increases CTLA4 promoter activity, with reporter assays showing the T allele produces more CTLA-4 transcription than the C allele. In functional studies, T allele carriers show increased CTLA-4 cell-surface expression, particularly when combined with the rs231775 AA genotype. The most notable clinical application is in rheumatoid arthritis: patients with at least one T allele showed an odds ratio of 5.88 for achieving satisfactory EULAR response on abatacept treatment.
Two copies of the T allele — highest CTLA-4 promoter activity and strongest abatacept response predictor
You carry two copies of the T allele at the CTLA4 -318 promoter position. This is a rare genotype — approximately 0.5% of people globally, and less than 1% in most populations. Your CTLA-4 promoter shows the highest transcriptional activity of the three genotypes. Functional studies show T allele homozygotes have the greatest CTLA-4 mRNA and cell-surface protein expression, particularly when also carrying the rs231775 AA genotype. The pharmacogenomic implication for abatacept response in RA is the most concrete clinical finding, extrapolated from data on T allele carriers. Autoimmune disease susceptibility from this variant alone remains inconsistently supported in the literature.